First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

PURPOSE: OX40, a receptor transiently expressed by T cells upon antigen recognition, is associated with costimulation of effector T cells and impairment of regulatory T-cell function. This first-in-human study evaluated MOXR0916, a humanized effector-competent agonist IgG(1) monoclonal anti-OX40 ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Tae Won, Burris, Howard A., de Miguel Luken, Maria J., Pishvaian, Michael J., Bang, Yung-Jue, Gordon, Michael, Awada, Ahmad, Camidge, D. Ross, Hodi, F. Stephen, McArthur, Grant A., Miller, Wilson H., Cervantes, Andres, Chow, Laura Q., Lesokhin, Alexander M., Rutten, Annemie, Sznol, Mario, Rishipathak, Deepali, Chen, Shang-Chiung, Stefanich, Eric, Pourmohamad, Tony, Anderson, Maria, Kim, Jeong, Huseni, Mahrukh, Rhee, Ina, Siu, Lillian L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662912/
https://www.ncbi.nlm.nih.gov/pubmed/35699599
http://dx.doi.org/10.1158/1078-0432.CCR-21-4020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662912/
https://www.ncbi.nlm.nih.gov/pubmed/35699599
http://dx.doi.org/10.1158/1078-0432.CCR-21-4020

Ejemplares similares